Table II.
Pharmacokinetic Parameters of Navitoclax After Oral Administration and Serum Concentrations of Rituximab Following Intravenous Infusion
| A. |
N | Navitoclax (Week 1 Day 2) |
||
|---|---|---|---|---|
| Dose | tmax, h |
Cmax, µg/mL |
AUC24, µg•h/mL |
|
| 200mg | 4 | 6.5 ± 1.0 | 3.35 ± 1.45 | 46.4 ± 16.2 |
| 250mg | 20 | 7.5 ± 4.3 | 3.70 ± 1.36 | 59.1 ± 24.2 |
| 325mg | 3 | 5.5 ± 2.8 | 3.94 ± 1.55 | 57.8 ± 26.2 |
| All doses | 27 | 7.1 ± 3.9 | -- | -- |
| B. | ||||
|---|---|---|---|---|
| Time point | N | Rituximab Serum Concentration, µg/mL | ||
| After first infusion | 27 | 220 ± 69.4 | ||
| Before fourth infusion |
23 | 178 ± 63.0 | ||
| After fourth infusion | 22 | 387 ± 104 | ||
| 1 week posttreatment | 20 | 240 + 77.8 | ||
| 1 month posttreatment |
18 | 107 ± 52.1 | ||
| 3 month posttreatment |
10 | 30.8 ± 38.2 | ||
A. Mean ± SD pharmacokinetic parameters for navitoclax. B. Mean ± SD serum concentrations of rituximab following first, third, and fourth infusions. Postinfusion samples were taken immediately after completion of the infusion. AUC24, area under the curve from time zero to 24 h; Cmax, maximum plasma concentration; tmax, time to Cmax.